



## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Importer of Controlled Substances Application: GE Healthcare

[Docket No. DEA-697]

**AGENCY:** Drug Enforcement Administration, Justice.

**ACTION:** Notice of application.

**SUMMARY:** GE Healthcare applied to be registered as an importer of the following basic class(es) of a controlled substance: Cocaine.

**DATES:** Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER]. Such persons may also file a written request for a hearing on the application on or before [INSERT DATE 30 DAYS AFTER DATE OF PUBLICATION IN THE FEDERAL REGISTER].

**ADDRESSES:** Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

**SUPPLEMENTARY INFORMATION:** In accordance with 21 CFR 1301.34(a), this is notice that on July 20, 2020, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights,

Illinois 60004-1412, applied to be registered as an importer of the following basic class(es) of a controlled substance:

| <b>Controlled Substance</b> | <b>Drug Code</b> | <b>Schedule</b> |
|-----------------------------|------------------|-----------------|
| Cocaine                     | 9041             | II              |

The company plans to import small quantities of Ioflupane, in the form of three separate analogues of cocaine, to validate production and quality control systems, for a reference standard, and for producing material for a future investigational new drug submission.

Supplies of this particular controlled substances are not available in the form needed within the current domestic supply of the United States.

**William T. McDermott,**  
*Assistant Administrator.*

[FR Doc. 2020-17437 Filed: 8/10/2020 8:45 am; Publication Date: 8/11/2020]